Clintec Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Clintec's estimated annual revenue is currently $62.3M per year.(i)
  • Clintec's estimated revenue per employee is $201,000

Employee Data

  • Clintec has 310 Employees.(i)
  • Clintec grew their employee count by -16% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.8M23-12%N/AN/A
#2
$4.1M30-19%N/AN/A
#3
$71M300-3%N/AN/A
Add Company

Clintec is an innovative, medium-sized, woman-owned, global Contract Research Organization providing global full and functional service support to the pharmaceutical, biotechnology and medical device industries. We are headquartered in the UK and have grown our clinical research business organically over the past 20 years. What We Do We are a global contract clinical research organisation that works with the best clinical experts to deliver a unique mix of technical, operational and scientific expertise in drug development. Where people's lives are involved, there's always more to be done, innovation to be discovered. We turn ideas into reality to meet patients needs to bring new medicines to market. We use e-clinical technologies to see the big picture in the smallest detail and provide a customized clinical service ensuring excellence at every stage. Why Choose Clintec At Clintec we believe flexibility is the key to success when working with our clients. We endeavor to meet our clients needs by being proactive and have created an environment that fosters this approach with our teams. Based in over 50 countries , our expertise is vast, yet our approach is simple: were focused, flexible and forward-thinking. FOCUSED: In clinical research every second counts. We take time to get things right first time. We see the bigger picture even while scrutinizing the smallest of details. FLEXIBLE: Every challenge is different, so every solution should be different too. We bring together a customized team for each challenge. We tailor our services to not just meet expectations, but exceed them. FORWARD THINKING: Were leaders, not followers. If there's a way to make something happen, well find it. Impossible isnt in our vocabulary.

keywords:N/A

N/A

Total Funding

310

Number of Employees

$62.3M

Revenue (est)

-16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Clintec's People

NameTitleEmail/Phone
1
Clinical Project SpecialistReveal Email/Phone
2
Senior CRA (Embedded-MSD Oncology)Reveal Email/Phone
3
Project Finance ManagerReveal Email/Phone
4
Logistics SpeciailistReveal Email/Phone
5
Senior Clinical Research AssociateReveal Email/Phone
6
Associate DirectorReveal Email/Phone
7
Clinical Research Associate 2Reveal Email/Phone
8
Associate Director Clinical OperationsReveal Email/Phone
9
Executive Administration ManagerReveal Email/Phone
10
Senior Clinical Trial CoordinatorReveal Email/Phone

Clintec News

2022-04-19 - CRO Services Market Size, Scope And Outlook | Covance Inc ...

... PSI, ICON plc, IQVIA, Med pace, Parexel International Corporation, KCR S.A, PRA Health Sciences Clintec, Pharmaceutical Product Development, LLC.

2022-04-19 - Pharmacovigilance (PV) Outsourcing Market Size, Outlook ...

Accenture, C3i Solutions, Clintec, Covance, Deloitte Touche Tohmatsu Limited, ELC Group, Ergomed, iGATE Corporation, iMED Global Corporation, IQVIA,...

2022-04-17 - CRO Services Market Size, Scope And Forecast | Covance Inc ...

... IQVIA, Med pace, Parexel International Corporation, KCR S.A, PRA Health Sciences Clintec, Pharmaceutical Product Development, LLC.

2010-08-19 - ClinTec International Receives £8M Minority Investment from Elephant Capital

ClinTec International, a global Clinical Research Organisation, received an £8m majority investment from London AIM market listed private equity firm Elephant Capital plc. Through this investment, Elephant has acquired a significant minority stake in the company. Managing Partner of Elephant Ca ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$84M320N/AN/A
#2
$85.3M32566%N/A
#3
$75.2M3349%N/A
#4
$15M335N/AN/A
#5
$41.9M3359%N/A